UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO
EndowmentPosition in NVS — Novartis AG
CIK 1019231
AUSTIN, TX
Position in NVS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$770,905
-$2,488,932 QoQ
Shares Held
4,919
-77.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
#708
of 1,603 holders
Holding Since
Sep 2022
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO holds $7,291,310 across 9 Drug Manufacturers - General names. NVS ranks #3 (10.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
165,020 | $3,973,681 | |
| 2 | LLY |
ELI LILLY & Co
|
1,114 | $1,336,165 | |
| 3 | NVS |
Novartis AG
This page
|
4,919 | $770,905 | |
| 4 | JNJ |
Johnson & Johnson
|
1,678 | $426,161 | |
| 5 | ABBV |
AbbVie Inc.
|
1,204 | $302,974 | |
| 6 | MRK |
Merck & Co., Inc.
|
1,783 | $229,115 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
950 | $120,023 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
1,460 | $84,125 |
All Filings in NVS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $770,905 | 4,919 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $3,259,837 | 21,341 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $533,694 | 3,871 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $790,727 | 6,166 | Shares | Sole | 2025-11-13 | |
| 2022-09-30 | $1,064 | 14 | Shares | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||